経口去痰薬の世界市場レポート 2025年

経口去痰薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年には年間平均成長率（CAGR）4.7％で52億6,000万米ドルに成長します。予測期間の成長は、研究開発投資の増加、天然・ハーブ去痰剤需要の拡大、新製品の規制承認、ヘルスケア支出の増加、革新的マーケティング戦略の採用などに起因すると考えられます。予測期間における主な動向としては、投薬管理のためのデジタルヘルスプラットフォームの統合、持続可能なパッケージングと製造慣行へのシフト、複数の呼吸器症状をターゲットとした併用療法の開発、遺伝子プロファイリングに基づく個別化医療アプローチ、患者中心のケアと遠隔医療サービスの重視、創薬と開発のための人工知能とビッグデータ分析の活用などが挙げられます。

経口去痰薬市場は、呼吸器疾患の有病率の増加により成長する見込みです。これらの疾患は、肺や気道などの呼吸器系に影響を及ぼし、大気汚染、喫煙、呼吸器感染症、喘息やCOPDなどの慢性疾患などの要因によって引き起こされます。経口去痰薬は、粘液を取り除き、呼吸を楽にし、全体的な回復をサポートすることで、症状を緩和し、呼吸器の健康を改善する上で重要な役割を果たします。例えば、National Center for Health Statisticsのデータによると、米国の成人の喘息有病率は2021年の8.4％から2022年には8.7％に上昇し、喘息エピソードも同期間に3.3％から3.7％に増加します。さらに、Lancet誌は、2021年夏に呼吸器疾患の原因ウイルスであるRSVの新規症例が2020-21年冬と比べて9.50%増加したと報告しており、経口去痰薬の需要拡大をさらに浮き彫りにしています。

経口去痰薬市場の主要企業は、オーガニック・ブルーベリー香料を製品に取り入れることで、クリーンな原材料を求める消費者の嗜好に応えています。このアプローチは、自然療法を求める健康志向の消費者に対応しています。例えば、Genexa Inc.は2022年11月に天然ブルーベリー香料を使用した大人用の新しい咳止め・胸づまり薬を発売しました。この製品は、ジェネクサ社初の最大強度の咳止め・去痰薬で、類似製品によく見られる人工成分に代わるクリーンな代替品を提供します。この新発売は、風邪やインフルエンザの季節に消費者により良い選択肢を提供し、医薬品に含まれる人工添加物に対する懸念に対処することを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界経口去痰薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の経口去痰薬市場：成長率分析
• 世界の経口去痰薬市場の実績：規模と成長, 2019-2024
• 世界の経口去痰薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界経口去痰薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の経口去痰薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 分泌促進剤
• 粘液溶解薬
• 世界の経口去痰薬市場剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口固形物
• 経口液
• 吸入剤
• 世界の経口去痰薬市場薬による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 処方薬
• 市販薬
• 世界の経口去痰薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売店とドラッグストア
• オンライン薬局
• 世界の経口去痰薬市場分泌促進剤のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• グアイフェネシン
• ヨウ化カリウム
• 世界の経口去痰薬市場粘液溶解薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アセチルシステイン
• ブロムヘキシン
• カルボシステイン

第7章 地域別・国別分析

• 世界の経口去痰薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の経口去痰薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 経口去痰薬市場：競合情勢
• 経口去痰薬市場：企業プロファイル
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline（GSK）plc
• Merck KGaA
• Reckitt Benckiser Group PLC
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca plc
• Aurobindo Pharma
• Cipla Inc.
• Dr. Reddy's Laboratories
• Hikma Pharmaceuticals PLC
• C.H. Boehringer Sohn AG And Co. KG
• Lupin Pharmaceuticals
• Taro Pharmaceutical Industries Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 経口去痰薬市場2029：新たな機会を提供する国
• 経口去痰薬市場2029：新たな機会を提供するセグメント
• 経口去痰薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

An oral expectorant is a type of medication designed to be taken by mouth to aid in clearing mucus and phlegm from the airways, lungs, bronchi, and trachea. These medications function by thinning and loosening the mucus, facilitating its easier expulsion through coughing from the respiratory tract.

The primary categories of oral expectorants include secretion enhancers and mucolytics. Secretion enhancers are medications that boost the production and release of mucus from the respiratory system, assisting in the clearance of respiratory secretions. These medications are available in various dosage forms such as oral solids, oral liquids, and inhalants. They encompass both prescription drugs and over-the-counter drugs and are distributed through channels including hospital pharmacies, retail stores, drug stores, and online pharmacies.

The oral expectorant market research report is one of a series of new reports from the business research company that provides oral expectorant market statistics, including oral expectorant industry global market size, regional shares, competitors with an oral expectorant market share, detailed oral expectorant market segments, market trends and opportunities, and any further data you may need to thrive in the oral expectorant industry. This oral expectorant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral expectorant market size has grown steadily in recent years. It will grow from $4.18 billion in 2024 to $4.38 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to increasing prevalence of respiratory illnesses, rising demand for over-the-counter medications, growing geriatric population, rising pollution levels, increasing awareness about respiratory health, and expansion of pharmaceutical distribution channels.

The oral expectorant market size is expected to see steady growth in the next few years. It will grow to $5.26 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to increasing investments in research and development, increasing investments in research and development, growing demand for natural and herbal expectorants, regulatory approvals for new products, rising healthcare expenditure, and adoption of innovative marketing strategies. Major trends in the forecast period include integration of digital health platforms for medication management, shift towards sustainable packaging and manufacturing practices, development of combination therapies targeting multiple respiratory symptoms, personalized medicine approaches based on genetic profiling, emphasis on patient-centric care and telemedicine services, and utilization of artificial intelligence and big data analytics for drug discovery and development.

The oral expectorant market is poised for growth due to the increasing prevalence of respiratory illnesses. These illnesses affect the respiratory system, including the lungs and airways, and are caused by factors such as air pollution, smoking, respiratory infections, and chronic conditions such as asthma and COPD. Oral expectorants play a vital role in alleviating symptoms and improving respiratory health by clearing mucus, easing breathing, and supporting overall recovery. For example, data from the National Center for Health Statistics shows a rise in asthma prevalence among adults in the United States from 8.4% in 2021 to 8.7% in 2022, along with an increase in asthma episodes from 3.3% to 3.7% during the same period. Additionally, The Lancet reported a 9.50% increase in new cases of RSV, a respiratory illness-causing virus, in summer 2021 compared to winter 2020-21, further highlighting the growing demand for oral expectorants.

Key players in the oral expectorant market are responding to consumer preferences for clean ingredients by incorporating organic blueberry flavoring into their products. This approach caters to health-conscious consumers seeking natural remedies. For instance, Genexa Inc. introduced a new cough and chest congestion medicine for adults with natural blueberry flavoring in November 2022. This product, the first maximum-strength cough suppressant and expectorant from Genexa, offers a clean alternative to artificial ingredients commonly found in similar products. The launch aims to provide consumers with better options during cold and flu seasons, addressing concerns about artificial additives in medicines.

In May 2024, Sun Pharmaceutical Industries Ltd. acquired Taro Pharmaceutical Industries Ltd. for $347.73 million. This acquisition strengthens Sun Pharma's position in the pharmaceutical market, particularly in off-patent pharmaceuticals, prescriptions, and over-the-counter products, including oral expectorants.

Major companies operating in the oral expectorant market are Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline (GSK) plc, Merck KGaA, Reckitt Benckiser Group PLC, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca plc, Aurobindo Pharma, Cipla Inc., Dr. Reddy's Laboratories, Hikma Pharmaceuticals PLC, C.H. Boehringer Sohn AG And Co. KG, Lupin Pharmaceuticals, Taro Pharmaceutical Industries Ltd., Perrigo Company plc, Biocon India Private Limited, Cadila Healthcare Ltd., Wockhardt Ltd, Genexa Inc.

North America was the largest region in the oral expectorant market in 2024. The regions covered in the oral expectorant market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral expectorant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral expectorant market consists of sales of products such as combination expectorants and cough suppressants, natural and homeopathic expectorants, expectorant lozenges and troches, multisymptomatic cold and flu medications containing expectorants, and pediatric expectorants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Expectorant Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral expectorant market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral expectorant ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral expectorant market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Secretion Enhancer; Mucolytics
• 2) By Dosage Form: Oral Solids; Oral Liquids; Inhalants
• 3) By Medication: Prescription drugs; Over The Counter Drugs
• 4) By Distribution Channel: Hospital Pharmacy; Retail Store And Drug Store; Online Pharmacies
• Subsegments:
• 1) By Secretion Enhancer: Guaifenesin; Potassium Iodide
• 2) By Mucolytics: Acetylcysteine; Bromhexine; Carbocisteine
• Companies Mentioned: Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; Abbott Laboratories Ltd; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oral Expectorant Market Characteristics

3. Oral Expectorant Market Trends And Strategies

4. Oral Expectorant Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Oral Expectorant Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oral Expectorant PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oral Expectorant Market Growth Rate Analysis
• 5.4. Global Oral Expectorant Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oral Expectorant Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oral Expectorant Total Addressable Market (TAM)

6. Oral Expectorant Market Segmentation

• 6.1. Global Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Secretion Enhancer
• Mucolytics
• 6.2. Global Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Solids
• Oral Liquids
• Inhalants
• 6.3. Global Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prescription drugs
• Over The Counter Drugs
• 6.4. Global Oral Expectorant Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Store And Drug Store
• Online Pharmacies
• 6.5. Global Oral Expectorant Market, Sub-Segmentation Of Secretion Enhancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Guaifenesin
• Potassium Iodide
• 6.6. Global Oral Expectorant Market, Sub-Segmentation Of Mucolytics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acetylcysteine
• Bromhexine
• Carbocisteine

7. Oral Expectorant Market Regional And Country Analysis

• 7.1. Global Oral Expectorant Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oral Expectorant Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oral Expectorant Market

• 8.1. Asia-Pacific Oral Expectorant Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oral Expectorant Market

• 9.1. China Oral Expectorant Market Overview
• 9.2. China Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oral Expectorant Market

• 10.1. India Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oral Expectorant Market

• 11.1. Japan Oral Expectorant Market Overview
• 11.2. Japan Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oral Expectorant Market

• 12.1. Australia Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oral Expectorant Market

• 13.1. Indonesia Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oral Expectorant Market

• 14.1. South Korea Oral Expectorant Market Overview
• 14.2. South Korea Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oral Expectorant Market

• 15.1. Western Europe Oral Expectorant Market Overview
• 15.2. Western Europe Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oral Expectorant Market

• 16.1. UK Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oral Expectorant Market

• 17.1. Germany Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oral Expectorant Market

• 18.1. France Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oral Expectorant Market

• 19.1. Italy Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oral Expectorant Market

• 20.1. Spain Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oral Expectorant Market

• 21.1. Eastern Europe Oral Expectorant Market Overview
• 21.2. Eastern Europe Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oral Expectorant Market

• 22.1. Russia Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oral Expectorant Market

• 23.1. North America Oral Expectorant Market Overview
• 23.2. North America Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oral Expectorant Market

• 24.1. USA Oral Expectorant Market Overview
• 24.2. USA Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oral Expectorant Market

• 25.1. Canada Oral Expectorant Market Overview
• 25.2. Canada Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oral Expectorant Market

• 26.1. South America Oral Expectorant Market Overview
• 26.2. South America Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oral Expectorant Market

• 27.1. Brazil Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oral Expectorant Market

• 28.1. Middle East Oral Expectorant Market Overview
• 28.2. Middle East Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oral Expectorant Market

• 29.1. Africa Oral Expectorant Market Overview
• 29.2. Africa Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oral Expectorant Market Competitive Landscape And Company Profiles

• 30.1. Oral Expectorant Market Competitive Landscape
• 30.2. Oral Expectorant Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Oral Expectorant Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. GlaxoSmithKline (GSK) plc
• 31.3. Merck KGaA
• 31.4. Reckitt Benckiser Group PLC
• 31.5. Viatris Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Sun Pharmaceutical Industries Ltd.
• 31.8. AstraZeneca plc
• 31.9. Aurobindo Pharma
• 31.10. Cipla Inc.
• 31.11. Dr. Reddy's Laboratories
• 31.12. Hikma Pharmaceuticals PLC
• 31.13. C.H. Boehringer Sohn AG And Co. KG
• 31.14. Lupin Pharmaceuticals
• 31.15. Taro Pharmaceutical Industries Ltd.

32. Global Oral Expectorant Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Expectorant Market

34. Recent Developments In The Oral Expectorant Market

35. Oral Expectorant Market High Potential Countries, Segments and Strategies

• 35.1 Oral Expectorant Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oral Expectorant Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oral Expectorant Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer